Cadonilimab（AK104）is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4.
This is a single-arm, multicenter, open-label, phase II study, the purpose of this study is to evaluate the efficacy and safety of Cadonilimab plus radiotherapy in participants with locally advanced cervical cancer who do not tolerate chemotherapy.
Able to understand and voluntarily sign written informed consent.
Women aged ≥18 years at the time of study entry.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-2.
Life expectancy ≥12 weeks.
Other histological types of cervical cancer (eg, neuroendocrine carcinoma, small cell carcinoma, sarcoma, etc).
Evidence of distant metastases.
Have received total hysterectomy.
Subject with other active malignancies within 2 years prior enter the study.
Chongqing University Cancer Hospital
Lead sponsor
Liaoning Cancer Hospital & Institute
Collaborator
Henan Cancer Hospital
Collaborator
Fujian Cancer Hospital
Collaborator